NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT07760909

Not Yet RecruitingNA

Sponsor: Vanderbilt University Medical Center

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Obesity, Bariatric Surgery

Interventions: Bariatric surgery, Stable isotope tracer infusion, MRI/MRE, Research tissue collection during planned bariatric surgery

This prospective, single-center pilot study will evaluate metabolic flux dysregulation in adults with obesity and suspected or confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) who are scheduled for protocol-eligible bariatric surgery at Vanderbilt University Medical Center. Participants will undergo research assessments before surgery, during the planned bariatric surgery encounter, and approximately 6 months after surgery. The study uses non-radioactive stable isotope tracer infusions, serial blood sampling, abdominal MRI/MRE, and research tissue specimens collected only during clinically planned bariatric surgery to quantify hepatic and extrahepatic metabolic fluxes. The primary objective is to determine how hepatic citric acid cycle flux and related metabolic pathways change after bariatric surgery and how these metabolic measures relate to liver fat, liver stiffness, and biopsy-graded MASLD/MASH severity.

Eligibility overview

Sex: ALL

Age: 21 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Scheduled and clinically cleared for protocol-eligible bariatric surgery at Vanderbilt University Medical Center.
* BMI ≥40 kg/m², or BMI \>35 kg/m² with at least one obesity-associated comorbidity, such as type 2 diabetes, cardiovascular disease, hypertension, hyperlipidemia, obstructive sleep apnea, MASLD, osteoarthritis, or polycystic ovarian syndrome.
* Able and willing to complete study procedures, including informed consent, questionnaires, blood draws, MRI/MRE imaging, stable isotope tracer infusion, and research tissue collection during planned bariatric surgery.
* Able to provide informed consent in English.

Exclusion Criteria:

* Contraindication to MRI/MRE, including implanted cardiac defibrillator, pacemaker, or other MRI-incompatible implanted device.
* Prior gastric or intestinal surgery, pancreatic surgery, or other prior surgery that, in the judgment of the study team or bariatric surgeon, would interfere with study procedures or outcome interpretation.
* Active cancer or ongoing cancer treatment.
* Presence or history of HIV infection.
* Alcohol use above study-defined limits: more than 14 alcoholic drinks per week for men or more than 7 alcoholic drinks per week for women, or illicit drug use that would interfere with safe participation or interpretation of study results.
* Anemia or other hematologic condition that would increase risk from study blood collection.
* Abnormal ECG or clinically significant cardiovascular finding that would increase risk from study procedures.
* Impaired renal function or other clinically significant condition that would increase risk from study participation.
* Known Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, or other non-MASLD chronic liver disease that would confound interpretation of study outcomes.
* Any medical, surgical, or safety condition that, in the judgment of the PI, clinical co-investigator, CRC staff, anesthesia team, or bariatric surgeon, would make participation unsafe or interfere with completion of study procedures.